The overexpression of MDM2 in DDLPS is linked with worse prognosis and poor response to chemotherapy and so MDM2-p53 interaction has garnered interest as a therapeutic target for DDLPS and other malignancies [24]. Here, MDM2 is linked to dedifferentiated liposarcoma.